Fermenta Biotech Ltd Q1 FY22 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Management growth scorecard
Revenue
Category 2
Margin
Category 3
Fundraise
N/A
Order
N/A
Capex
Yes
1 of 3 growth signals are positive — mixed outlook.
Full analysisRevenue guidance
Category 2- The company aims to grow both topline and margins, targeting a four-digit crore revenue in 4-6 years depending on efficiency of plan implementation (Page 15).
- Expect human vitamin D3 volumes to continue growing, though growth rate may taper post-COVID; animal segment worst phase is likely over, expected to stabilize (Page 12-13).
- Capacity expansions, including 25% additional vitamin D3 capacity (plant IV), expected to be fully commissioned by Q2 FY2022, boosting volumes (Page 13-14).
- New nutritional ingredient products like vitamin K1, premixes, minerals to contribute 30-40% revenue over next 4-5 years, supporting growth and diversification (Page 14).
- CAGR for medium-term revenue growth not precisely stated but implied steady sustainable growth with margin target of ~25% EBITDA (Page 14-15).
- Continued focus on new client acquisition and expanding market share in human vitamin D3, especially in the US (Page 9).
See what Fermenta Biotech Ltd management said on margin guidance — free account, 30 seconds.
Fundraise plans
- No specific mention of any current or future fundraising through debt or equity was made in the transcript.
- The company has undertaken significant capex (around Rs.150-200 Crores planned over 2-3 years) funded so far by internal accruals.
- There is mention of managing existing debt, with rental income servicing about Rs.75 Crores of loans comfortably.
- No indications of raising fresh equity or debt capital were discussed during the call.
- Focus appears to be on utilizing internal resources and operational cash flows for expansion and project funding.
- The company is monitoring market conditions and may consider options like monetizing real estate to manage finances, but no formal plans cited.
See what Fermenta Biotech Ltd management said on order book — free account, 30 seconds.
Capex plans
Yes- Planned capex of approximately ₹150 to ₹200 Crores over the next 2-3 years.
- Initial ₹50-60 Crores expected to be spent in the current year.
- Investments focused on:
- - Expansion of Vitamin D3 capacity (additional 22-25% planned).
- - Setting up new facilities for nutritional ingredients like minerals and Vitamin K1.
- - Establishment of a premix plant for combining various minerals and vitamins.
- - Enhancements in fermentation capacities through a new greenfield project in Saykha.
- - Utilization and expansion in existing plants where feasible.
- Current Vitamin D3 capacity expansion partly commercialized; full commissioning expected by Q2 FY2022.
- Strategic focus on strengthening nutritional ingredient portfolio and value-added vitamin D3 formats.
Track Fermenta Biotech Ltd — get its next earnings analysis in your feed
Margin guidance
Category 3- Fermenta Biotech aims to achieve a four-digit crore topline in 4-6 years, focusing on both revenue and margin growth, with an emphasis on improving margins (Page 14).
- The company expects new products and forward/backward integration to grow nutritional ingredients to contribute 30-40% of increased revenues in 4-5 years (Page 14).
- Target EBITDA margin is approximately 25%, despite potential volatility from new products entering the market (Page 14).
- Capex plans of Rs. 150-200 Crores over the next 2-3 years will drive capacity expansions in vitamin D3, minerals, vitamin K1, and premix plants enhancing growth potential (Page 8, 13).
- Human nutrition capacity is near full utilization (~100%), with expansions expected to commission by Q2 FY2022, which should support volume and earnings growth (Page 12, 8).
- Animal nutrition segment is gradually recovering from a depressed market and further price improvements are anticipated (Page 11, 12).
- Business losses and one-time provisions from subsidiaries are expected to reduce, improving consolidated profitability going forward (Page 15, 17).
Order book
- The transcript does not explicitly mention the current or expected order book or pending orders for Fermenta Biotech Limited.
- Discussion focuses more on capacity expansion, product launches (such as 25-hydroxy-VD3), and market outlook.
- The company highlights delays due to resource allocation but confirms ongoing efforts to commercialize new products.
- Capacity utilization is near full on the human nutrition side, indicating healthy demand.
- Expansion projects for vitamin D3 capacity are underway with commissioning expected mostly by Q2 FY2022.
- No specific figures or timelines related to order book or pending orders are provided in the transcript.
How does Fermenta Biotech Ltd rank vs peers in Pharmaceuticals & Biotechnology?
Pro featureHow does Fermenta Biotech Ltd rank in Pharmaceuticals & Biotechnology?
Compare Fermenta Biotech Ltd against every Pharmaceuticals & Biotechnology company (Q1 FY22) on revenue, margins and earnings-call signals.
Continue your research
What Fermenta Biotech Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- IOL Chemicals (Q1 FY27)
Expansion plans supported by capex of INR 200-250 crores annually, with 60% towards expansion/new products and 40% towards efficiency improvements. Key concall…
- Innova Captab Ltd (Q1 FY27)
The company is confident of achieving 20%+ volume growth backed by steady ramp-up in Jammu and existing facilities. Key concall takeaways from Innova Captab…
- Glenmark Pharma. (Q1 FY27)
Chronic respiratory segment in India showing over 25% growth; oncology and cardiovascular segments also strong. Key concall takeaways from Glenmark…
- Strides Pharma Science Ltd (Q1 FY27)
markets continue to be broad-based growth drivers, with 17% YoY growth and expansion in B2B and B2C markets including Europe, UK, Nordics, Africa, LATAM, MENA…